Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Short Candidates -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (878)	12/13/2017 1:56:23 PM
From: tuck	1 Recommendation Recommended By DewDiligence_on_SI Read Replies (1) \| Respond to of 897

Actually added to my position on GALT this morning. Since the trial fail and spin, there has been no financing, despite the rebound. In light of this, the following snip from the latest quarterly report is very relevant: "As of September 30, 2017, the Company had $7.0 million of non-restricted cash and cash equivalents. The Company believes it has sufficient cash to fund currently planned operations and research and development activities through December 31, 2017." This for a company that is apparently planning on pursuing a late stage NASH trial, and has other earlier programs. And no partners. Cheers, Tuck